SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
|Videos|May 13, 2020
When to suspect atopic dermatitis or alternate diagnoses
Author(s)Jessica Barry
Jonathan Silverberg, M.D., Ph.D., MPH, discusses criteria to keep in mind when evaluating a patient with possible atopic dermatitis.
Advertisement
In a presentation given during the
The Revolutionizing Atopic Dermatitis live meeting is scheduled to take place December 5-7, 2020 in Chicago.
Advertisement
Related to this article
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5